(19) World Intellectual Property Organization

International Bureau



(43) International Publication Date 23 February 2006 (23.02.2006)

PCT

(10) International Publication Number WO 2006/021000 A3

(51) International Patent Classification:

C07D 495/04 (2006.01) **A61K 31/425** (2006.01) **C07D 513/04** (2006.01) **A61P 25/24** (2006.01)

(21) International Application Number:

PCT/US2005/029383

(22) International Filing Date: 18 August 2005 (18.08.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/603,347 19 August 2004 (19.08.2004) US

(71) Applicant (for all designated States except US): AVENTIS PHARMACEUTICALS INC. [US/US]; 300 Somerset Corporate Boulevard, Bridgewater, New Jersey 08807-2854 (US).

(72) Inventors; and

- (75) Inventors/Applicants (for US only): FINK, David Marc [US/US]; 1 Kensington Court, Lebanon, New Jersey 08833 (US). CHIANG, Yulin [US/US]; 24 Vom Eigen Drive, Convent Station, New Jersey 07960 (US). COLLAR, Nicola Dawn [GB/US]; 64 Monroe Street, Hoboken, New Jersey 07030 (US).
- (74) Agents: STRUPCZEWSKI, Joseph et al.; sanofi-aventis, Route 202-206, P. O. Box 6800, Bridgewater, New Jersey 08807-0800 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:


with international search report

(88) Date of publication of the international search report:

15 June 2006

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.


(54) Title: SUBSTITUTED THIENOPYRROLE CARBOXYLIC ACID AMIDES, PYRROLOTHIAZOLE CARBOXYLIC ACID AMIDES, AND RELATED ANALOGS AS INHIBITORS OF CASEIN KINASE I EPSILON



(57) Abstract: The present invention discloses and claims compounds as inhibitors of human casein kinase I£ and methods for using said compounds for treating central nervous system diseases and disorders including mood disorders and sleep disorders. Pharmaceutical compositions comprising said compounds and a method for the preparation are also disclosed and claimed.

International application No

a. classification of subject matter C07D495/04 C07D513/04 A61K31/425 A61P25/24 According to International Patent Classification (IPC) or to both national classification and IPC **B. FIELDS SEARCHED** Minimum documentation searched (classification system followed by classification symbols) CO7D A61K A61P Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data, PAJ, BEILSTEIN Data, CHEM ABS Data C. DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages Category* Relevant to claim No. US 6 555 328 B1 (KEESLER GEORGE A ET AL) 1-27 29 April 2003 (2003-04-29) cited in the application Abstract; claims; example 10. Α MEGGIO, F. ET AL.: 1 - 27"RIBOFURANOSYL-BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF CASEIN KINASE-2 AND CASEIN KINASE-1" EUROPEAN JOURNAL OF BIOCHEMISTRY, BERLIN, vol. 187, no. 1, 1990, pages 89-94, XP000646580 ISSN: 0014-2956 The whole document, in particular the compounds of table 1. X Further documents are listed in the continuation of Box C. See patent family annex. Special categories of cited documents: *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the "A" document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another "Y" document of particular relevance; the claimed invention citation or other special reason (as specified) cannot be considered to involve an inventive step when the document is combined with one or more other such docudocument referring to an oral disclosure, use, exhibition or ments, such combination being obvious to a person skilled in the art. other means document published prior to the international filing date but later than the priority date claimed "&" document member of the same patent family Date of the actual completion of the international search . Date of mailing of the international search report 3 February 2006 01/03/2006 Name and mailing address of the ISA/ Authorized officer European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Weisbrod, T Fax: (+31-70) 340-3016



		FG1/U52005/029383	
C(Continua	ation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	
A	MASHHOON, N. ET AL.: "Crystal Structure of a Conformation-selective Casein Kinase-1 Inhibitor" J. BIOL.CHEM., vol. 275, no. 26, 2000, pages 20052-20060, XP002366003 The whole document.	1-27	
A	NING, K. ET AL.: "Circadian regulation of GABA-A receptor function by CKI-epsilon-CKI-delta in the rat suprachiasmatic nuclei" NATURE NEUROSCIENCE, NATURE AMERICA, INC, US, vol. 7, no. 5, May 2004 (2004-05), pages 489-490, XP002359687 ISSN: 1097-6256 The whole document, particularly reference to CKIepsilon-CKIdelta inhibitor IC261.	1-27	
P,A	WO 2005/061498 A (AVENTIS PHARMACEUTICALS INC; METZ, WILLIAM, A; HALLEY, FRANK; DUTRUC-R) 7 July 2005 (2005-07-07) Abstract; claims; examples.	1–27	
A	DATABASE BEILSTEIN Beilstein Institut zur Förderung der chemischen Wissenschaften, Frankfurt/Main, DE; XP002366005 Database Accession Nos. 5099280, 5108767, 5110689 (BRN's). & J. CHEM. SOC. PERKIN TRANS. 1, 1986, pages 501-506,	1-27	

Form PCT/ISA/210 (continuation of second sheet) (April 2005)

1



Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)							
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:							
1. X Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:							
Although claims 14-25 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compounds.							
Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:							
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).							
Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)							
This International Searching Authority found multiple inventions in this international application, as follows:							
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.							
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.							
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:							
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:							
Remark on Protest The additional search fees were accompanied by the applicant's protest.							
No protest accompanied the payment of additional search fees.							

nformation on patent family members

International application No

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
US 6555328	B1	29-04-2003	AU	767800 B2	27-11-2003
			ΑU	5468900 A	28-12-2000
			BR	0011437 A	05-03-2002
			CA	2375450 A1	14-12-2000
			EP	1183541 A1	06-03-2002
			JP	2003501074 T	14-01-2003
			MΧ	PA01011417 A	04-06-2002
			NO	20015972 A	05-02-2002
			NZ	514603 A	31-10-2003
			WO	0075669 A1	14-12-2000
			ZA	200108962 A	30-01-2003
WO 2005061498	 А	07-07-2005	NONE		